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Coronary tortuosity can hinder vessel wiring and equipment delivery and has been associated with low-er success rates and higher complications rates in per-
cutaneous coronary intervention (PCI).1-3 Coronary tortuosi-
ty affects the efficiency and success of chronic total occlusion 
(CTO)-PCI and is included both in the Japanese chronic total 
occlusion (J-CTO) score for predicting successful guidewire 
crossing within the first 30 minutes of the procedure,4 and 
the Progress-CTO score5 for predicting technical success. We 
examined a multicenter United States registry to determine the 
impact of tortuosity on outcomes of contemporary CTO-PCI.
Methods
Patient population. We examined the baseline clinical 
and angiographic characteristics and outcomes of CTO-PCIs 
performed between 2012 and 2016 at 14 United States cen-
ters: Appleton Cardiology, Appleton Wisconsin; Baylor Hamil-
ton Heart and Vascular Hospital, Dallas, Texas; Central Arkan-
sas VA Healthcare System, Little Rock, Arkansas; Columbia 
University, New York, New York; Henry Ford Hospital, De-
troit, Michigan; Massachusetts General Hospital, Boston, Mas-
sachusetts; Medical Center of the Rockies, Loveland, Colo-
rado; Piedmont Heart Institute, Atlanta Georgia; St. Joseph 
Medical Center, Bellingham Washington; St. Luke’s Health 
System’s Mid-America Heart Institute, Kansas City, Missouri; 
Torrance Memorial Center, Torrance, California; University 
of Pittsburgh Medical Center, Presbyterian University Hos-
pital, Pittsburgh, Pennsylvania; VA North Texas Health Care 
System, Dallas, Texas; and University of California, San Diego 
Healthcare System, San Diego, California. 
Enrollment was performed during only part of the study 
period in some centers due to participation in other studies. 
Data collection was performed both prospectively and ret-
rospectively and was recorded in a dedicated online database 
(Progress CTO: Prospective Global Registry for the Study 
of Chronic Total Occlusion Intervention; Clinicaltrials.gov 
Identifier: NCT02061436).5-9 The study was approved by 
the institutional review board of each site.
The Impact of Proximal Vessel Tortuosity on the 
Outcomes of Chronic Total Occlusion Percutaneous 
Coronary Intervention: Insights From a Contemporary 
Multicenter Registry
Judit Karacsonyi, MD1,2;  Dimitri Karmpaliotis, MD3;  Khaldoon Alaswad, MD4;  Farouc A. Jaffer, MD, PhD5; 
Robert W. Yeh, MD6;  Mitul Patel, MD7;  Ehtisham Mahmud, MD7;  Anthony Doing, MD8;  Catalin Toma, MD9; 
Barry Uretsky, MD10;  James Choi, MD11;  Jeffrey W. Moses, MD3;  Ajay Kirtane, MD3;  Manish Parikh, MD3; 
Ziad Ali, MD3;  William L. Lombardi, MD12;  David E. Kandzari, MD13;  Nicholas Lembo, MD13;  Santiago Garcia, MD14; 
Michael R. Wyman, MD15;  Jose R. Martinez-Parachini, MD1;  Aris Karatasakis, MD1;  Barbara A. Danek, MD1; 
Aya J. Alame, BA1;  Erica Resendes, MS1;  Bavana V. Rangan, BDS, MPH1;  Imre Ungi, MD, PhD2; 
Craig A. Thompson, MD, MMSc16;  Subhash Banerjee, MD1;  Emmanouil S. Brilakis, MD, PhD1,17
ABSTRACT: Introduction. We examined the impact of proximal vessel tortuosity on the outcomes of chronic total occlusion (CTO) 
percutaneous coronary intervention (PCI). Methods. The baseline clinical and angiographic characteristics and procedural out-
comes of 1618 consecutive CTO-PCIs performed between 2012 and 2016 at 14 United States centers in 1589 patients were reviewed. 
Results. Mean patient age was 65.3 ± 10.0 years and 85% were men. Moderate/severe proximal vessel tortuosity was present in 
35.7% of target lesions. Compared with non-tortuous lesions, tortuous lesions had longer length (30 mm [interquartile range, 20-
50 mm] vs 28 mm [interquartile range, 16-40 mm]; P<.001), more proximal cap ambiguity (36% vs 28%; P<.01), and more frequent 
utilization of the retrograde approach (52% vs 37%; P<.001). Moderate/severe proximal vessel tortuosity was associated with lower 
technical success rates (84.1% vs 91.3%; P<.001) and procedural success rates (82.3% vs 89.9%; P<.001), but similar incidence of 
major cardiac adverse events (3.0% vs 2.5%; P=.59). Moderate/severe tortuosity was associated with longer procedure time and 
fluoroscopy time, higher air kerma radiation dose, and larger contrast volume. Conclusion. In a contemporary multicenter registry, 
moderate/severe proximal vessel tortuosity was present in approximately one-third of target CTO lesions and was associated with 
more frequent use of the retrograde approach and lower success rates, but similar complication rates.
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Definitions. Coronary CTOs were defined as coronary 
lesions with Thrombolysis in Myocardial Infarction (TIMI) 
grade 0 flow of at least 3-month duration. Estimation of the oc-
clusion duration was based on first onset of anginal symptoms, 
prior history of myocardial infarction in the target-vessel 
territory, or comparison with a prior angiogram. Calcifica-
tion was assessed by angiography as mild (spots), moderate 
(involving ≤50% of the reference lesion diameter), or severe 
(involving >50% of the reference lesion diameter). 
Moderate proximal vessel tortuosity was defined as the pres-
ence of at least 2 bends >70° or 1 bend >90° and severe tor-
tuosity as 2 bends >90° or 1 bend >120° in the CTO vessel. 
The J-CTO score was calculated as described by Morino 
et al.4 The Progress CTO score was calculated as described by 
Christopoulos et al.5 Technical success was defined as successful 
CTO revascularization with achievement of <30% residual 
diameter stenosis within the treated segment and restoration 
of TIMI grade 3 antegrade flow. Procedural success was defined 
as achievement of technical success with no in-hospital major 
adverse cardiac event (MACE). In-hospital MACE included 
any of the following adverse events prior to hospital discharge: 
death, myocardial infarction, urgent repeat target-vessel revas-
cularization with either PCI or coronary artery bypass graft 
(CABG) surgery, tamponade requiring either pericardiocen-
tesis or surgery, and stroke. Myocardial infarction was defined us-
ing the Third Universal Definition of Myocardial Infarction.10
Statistical analysis. Comparisons were performed be-
tween CTO-PCI procedures classified into two groups ac-
cording to whether moderate or severe proximal tortuosity 
was present in the CTO target vessel or not. Continuous 
variables were presented as mean ± standard deviation or 
median (interquartile range) and were compared using the 
Student’s t-test or Wilcoxon rank-sum test, as appropriate. 
Categorical data were reported as frequencies or percent-
ages and compared using the Chi-squared test or Fisher’s 
exact test, as appropriate. Logistic regression analysis was 
performed to identify clinical and angiographic parame-
ters associated with technical success. Variables with P<.10 
on univariate analysis (age >70 years, gender, hypertension, 
dyslipidemia, left ventricular ejection fraction in units, con-
gestive heart failure and myocardial infarction, prior CABG, 
peripheral arterial disease and cerebrovascular disease, pres-
ence of moderate or severe calcification, proximal cap am-
biguity, prior failed CTO-PCI, presence of interventional 
collaterals, moderate or severe proximal vessel tortuosity, and 
CTO target vessel) were included in a multivariate model. 
All statistical analyses were performed with JMP 11.0 (SAS 
Institute). Two-sided P-values <.05 were considered statisti-
cally significant. 
Results
Baseline clinical characteristics. We analyzed 1618 
consecutive CTO-PCIs performed in 1589 patients. The 
baseline clinical characteristics of the study patients are pre-
sented in Table 1. Mean age was 65.3 ± 10.0 years and 85% 
of the study subjects were men. Nearly one-half of the pa-
tients had diabetes mellitus or prior myocardial infarction and 
approximately one-third had prior heart failure and prior 
CABG. Patients with moderate/severe tortuosity were more 
likely to have diabetes mellitus and prior CABG. 




Moderate or Severe 
Tortuosity (n = 566)
Mild or No Tortuosity 
(n = 1023)
P-Value
Age (years) 65.3 ± 10.0 65.1 ± 10.0 65.4 ± 10.0 .59
Men 85% 88% 84% .02
Body mass index (kg/m2) 30.6 ± 6.0 30.9 ± 6.0 30.5 ± 6.0 .30
Diabetes mellitus 44% 48% 42% .02
Hypertension 91% 91% 90% .78
Dyslipidemia 95% 96% 95% .51
Smoking (current) 26% 26% 26% .96
Left ventricular ejection fraction (%) 50 ± 14 49 ± 14 50 ± 14 .55
Family history of coronary artery disease 30% 31% 29% .63
Congestive heart failure 30% 32% 28% .09
Prior myocardial infarction 43% 47% 41% .03
Prior coronary bypass 36% 46% 31% <.001
Prior cerebrovascular disease 11% 11% 11% .88
Prior peripheral vascular disease 17% 17% 16% .66
Baseline creatinine (mg/dL) 1.0 (0.9-1.3) 1.1 (0.9-1.3) 1.0 (0.9-1.2) .04
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Angiographic characteristics. The angiographic char-
acteristics of the CTO target lesions are summarized in Table 
2. Moderate or severe proximal vessel tortuosity was present 
in 35.7%. The most common target vessel was the right cor-
onary artery (56%) followed by the left anterior descending 
artery (23%) and the circumflex (21%). The most common fi-
nal successful crossing strategy was antegrade wire escalation 
(41%) followed by retrograde (25%) and antegrade dissection 
and reentry (23%). Moderate or severe calcification was present 
in more than one-half of the lesions (57%), and interventional 
collaterals were present in 57%. 
Lesions with moderate or severe proximal vessel tortuosity 
were more complex, with higher J-CTO and Progress CTO 
scores and moderate or severe calcification. Moreover, tortuous 
lesions were longer and more likely to exhibit proximal cap 
ambiguity and to require retrograde crossing attempts (Table 2).
Table 2. Angiographic characteristics of the study lesions, classified according to proximal vessel tortuosity.
Variable Overall 
(n = 1618)
Moderate or Severe 
Tortuosity (n = 578)






  Right coronary artery 56% 57% 55%
  Left anterior descending 23% 10% 30%
  Left circumflex 21% 32% 14%
  Left main 0.01% 0.0% 0.2%
  Other 0.03% 0.9% 0%
J-CTO score 2.51 ± 1.24 3.21 ± 1.05 2.11 ± 1.16 <.001
Progress CTO score 1.11 ± 1.00 1.94 ± 0.87 0.65 ± 0.74 <.001
Calcification (moderate/severe) 57% 72% 48% <.001
Proximal cap ambiguity 31% 36% 28% <.01
In-stent restenosis 15% 14% 16% .27
Prior failure to open CTO 18% 20% 16% .047
Interventional collaterals 57% 52% 60% .01
Side branch at the proximal cap 47% 48% 46% .64
Blunt/no stump 64% 67% 63% .10
Vessel diameter (mm) 3.0 (2.5-3.0) 3.0 (2.5-3.0) 3.0 (2.5-3.0) .42
Occlusion length (mm) 30 (20-45) 30 (20-50) 28 (16-40) <.001
Successful crossing strategy
<.001
  Antegrade wiring 41% 32% 46%
  Retrograde 25% 31% 22%
  Antegrade dissection and reentry 23% 23% 22%
  None 11% 14% 9%
First crossing strategy
.02
  Antegrade wiring 69% 66% 71%
  Retrograde 19% 23% 16%
  Antegrade dissection and reentry 12% 11% 12%
Retrograde crossing attempt 42% 52% 37% <.001
Stents used (n) 2.5 ± 1.2 2.8 ± 1.2 2.4 ± 1.1 <.001
Guide-support techniques
  Guide-extension catheter 22% 24% 21% .08
  Side-branch anchor 3% 5% 2% <.01
  Distal anchor 1% 2% 0.5% <.01
  Other 1% 0.4% 1% .12
Data provided as mean ± standard deviation, percentage, or median (interquartile range).
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Procedural outcomes. Procedural outcomes are 
shown in Table 3 and Figure 1. Overall technical and pro-
cedural success rates were 89% and 87%, respectively, and 
the MACE rate was 2.7%. Lesions with moderate or se-
vere tortuosity had lower technical success rates (84% vs 
91%; P<.001) and procedural success rates (83% vs 90%; 
P<.001), but similar MACE rates (3.0% vs 2.5%; P=.59) as 
compared with cases with mild or no tortuosity. There was 
no difference between the various components of MACE 
(death, myocardial infarction, repeated PCI, stroke, emer-
gency CABG, and pericardiocentesis). However, on mul-
tivariable analysis, moderate or severe tortuosity was not 
independently associated with technical success (Figure 2). 
PCI of lesions with moderate or severe tortuosity required 
longer procedure and fluoroscopy times, higher air kerma 
radiation doses, and higher contrast volumes. 
The most common guide-support technique to address 
proximal vessel tortuosity was use of guide-catheter ex-
tensions followed by side-branch anchor and distal-anchor 
techniques (Table 2; Figure 3). Among the cases with mod-
erate or severe proximal vessel tortuosity, the most common-
ly used antegrade guide catheter was AL 1 (54 cases; 29.4%), 
while the most commonly used retrograde guide catheter 
was the EBU 4.0 (Figure 4). 
Discussion
The main findings of this study are that significant prox-
imal vessel tortuosity: (1) was present in approximately one-
third of target CTOs; (2) was associated with lower technical 
and procedural success, but similar complication rates; (3) 
required more supportive guide catheters and guide-catheter 
techniques to address tortuosity; and (4) required use of the 
retrograde approach more frequently to obtain success. 
Tortuosity is common among complex coronary lesions. 
Okamura et al reported 34.2% prevalence of proximal ves-
sel tortuosity in a Japanese multicenter CTO-PCI registry.11 
In an analysis of 1582 retrograde CTO-PCIs from the Eu-
roCTO club, Galassi et al reported moderate tortuosity in 
28.5% and severe tortuosity in 9.7%.12 Baykan et al reported 
Table 3. Procedural outcomes of the study patients, classified according to proximal vessel tortuosity.
Variable Overall 
(n = 1589)
Moderate or Severe 
Tortuosity (n = 566)




Technical success 88.7% 84.1% 91.3% <.001
Procedural success 87.2% 82.3% 89.9% <.001
Procedural time (min) 129 (90-194) 153 (108-210) 120 (82-184) <.001
Fluoroscopy time (min) 48 (29-77) 60 (38-94) 41 (26-68) <.001
Air kerma radiation dose (Gray) 3.24 (2.00-5.26) 3.85 (2.35-5.54) 2.95 (1.70-5.07) <.001
Contrast volume 275 (200-370) 293 (214-400) 263 (200-360) <.001
Major adverse cardiac events 2.70% 3.00% 2.54% .59
Death 0.57% 0.53% 0.59% .89
Acute Q-wave myocardial infarction 0% 0% 0% —
Acute myocardial infarction 0.94% 0.71% 1.08% .47
Redo PCI 0.25% 0.53% 0.10% .01
Stroke 0.25% 0.18% 0.29% .66
Emergency CABG 0.06% 0.18% 0.00% .18
Pericardiocentesis 0.94% 1.24% 0.78% .37
Data provided as percentage or median (interquartile range).
PCI = percutaneous coronary intervention; CABG = coronary artery bypass graft surgery.
FIGURE 1. Technical and procedural success and incidence of 
major adverse cardiac events (MACE) among study lesions, 
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a lower prevalence of severe tortuosity (10.4%) among 173 
CTO-PCIs, although tortuosity was associated with tech-
nical failure (odds ratio: 0.085; 95% confidence interval, 
0.013-0.579; P=.01), where severe tortuosity was defined as 
≥1 bend of 90° or more, or ≥3 bends of 45°-90° proximal to 
the diseased segment.1
The pathogenesis of coronary tortuosity remains unclear, 
but tortuosity is associated with increasing age, hypertension, 
atherosclerosis, and genetic predisposition.13-16 Han created a 
biomedical model of arterial buckling, 
demonstrating that arteries buckle due to 
high blood pressure, reduced axial stretch, 
or changes in the arterial wall stiffness and 
dimensions, lending support to the associ-
ation of tortuosity with hypertension, ag-
ing, atherosclerosis and other pathological 
arterial changes.14,17 
Several techniques have been devel-
oped to overcome the challenges associ-
ated with PCI of tortuous lesions. Wir-
ing of such lesions can be hindered by 
decreased wire torquability after passing 
the first curves and can be facilitated by 
using large size and supportive-shaped 
guide catheters and/or guide-catheter ex-
tensions, advancing wires through a mi-
crocatheter and using new-generation, 
composite-core wires or polymer-jacketed 
guidewires.18 Use of stiff wires, however, 
could straighten the vessel and possibly 
lead to the development of coronary 
“pseudolesions.”3 In our study, the most 
commonly used guide catheters in mod-
erate or severe proximal vessel tortuosi-
ty were the Amplatz left and extra back-
up guides, which provide strong guide-catheter support. 
Moreover, use of dissection/reentry crossing techniques 
can facilitate crossing of tortuous CTOs by tracking the 
vessel bends with low risk of exiting the adventitia and 
leading to perforation. The prevalence of moderate/severe 
calcification was high (72%) in the majority of patients 
with proximal vessel tortuosity and likely contributed to 
the use of the retrograde approach in over one-half of the 
study cohort. Ultimately, the use of the above techniques 
resulted in >80% procedural and technical success rates in 
this challenging group of CTO patients.
Study limitations. There was no core laboratory analysis 
of the study angiograms and no independent event adjudi-
cation, and therefore assessment of angiographic characteris-
tics was susceptible to operator-related bias. The CTO-PCI 
procedures were performed by centers with significant 
expertise in CTO-PCI; hence, these findings may not be 
generalizable to less experienced centers and operators. No 
follow-up data were available for analysis and the long-term 
outcomes associated with coronary tortuosity would require 
additional investigation. Lastly, the presence of tortuosity was 
determined by visual estimate.
Conclusion
In summary, moderate or severe proximal vessel tortuosity 
is common in CTO target lesions and is associated with low-
er efficiency and procedural success, but similar complication 
rates as compared with lesions with mild or no tortuosity. 
FIGURE 3. Guide-support techniques among study lesions, 
classified according to proximal vessel tortuosity.
FIGURE 2. Multivariable analysis for technical success. BMI = body mass index; 
LVEF = left ventricular ejection fraction; CABG = coronary artery bypass graft sur-
gery; CVD = cerebrovascular disease; PVD = peripheral vascular disease; CTO = 
chronic total occlusion; RCA = right coronary artery; LAD = left anterior descending 
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ed at University of Texas Southwestern Medical Center.19 
REDCap (Research Electronic Data Capture) is a secure, 
web-based application designed to support data capture 
for research studies, providing: (1) an intuitive interface for 
validated data entry; (2) audit trails for tracking data ma-
nipulation and export procedures; (3) automated export 
procedures for seamless data downloads to common statis-
tical packages; and (4) procedures for importing data from 
external sources.
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